
Dr. Adrian Kessler is on the verge of a breakthrough. His revolutionary gene-editing therapy promises to preserve and enhance cognitive function, offering new hope for neurodegenerative diseases. But when funding runs out, he is forced to accept an offer from Prometheus Biotech,...